August 2014

Experts Touch On Oncotype DX, Other Assays During Peer Exchange

Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.

The year was 1989, and I was one year away from finishing six years of residency in general surgery and urology.

If one had to choose a single word to describe the future of Obamacare, it would probably be "uncertain."

Practice-changing trends in the combined use of androgen deprivation therapy (ADT) and radiation therapy (RT) for the treatment of prostate cancer were highlighted recently in a review paper by Mack Roach III, MD, a professor of Radiation Oncology and Urology and chair of the Department of Radiation Oncology at the University of California, San Francisco.

Sipuleucel-T (Provenge), an immunotherapy tailor-made for men with metastatic castration-resistant prostate cancer (mCRPC) using their own white blood cells, is just as potent if it is manufactured while a patient is taking enzalutamide (Xtandi), and the two drugs seem to boost immunity more effectively when administered together.

It took just a minute and a half for a disgruntled patient to leave his deadly mark on a Nevada urology clinic, irreversibly changing the lives of everyone inside.

Sipuleucel-T (Provenge) is effective when given either before or after androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer (BRPC) who face a high risk of developing metastases, a study has found.

A physician's perspective, and the therapies he most often prescribes, can have a big influence on whether his patients with low-risk prostate cancer are treated or put on active surveillance, a study has found.

Prostate cancer that emerges when a man is 55 years of age or younger is a distinct phenotype of the disease, and should be treated and researched accordingly,

In recent studies, robotic-assisted surgery was explored as a treatment for both prostate and kidney cancers.

Men diagnosed with prostate cancer after being diagnosed with depression were less likely to undergo definitive treatment for their cancer and had worse overall survival.

Biomarkers. It's a term thrown around quite frequently in the cancer world.